← Eichor
Study identifier: NCT06291818 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Self-Adhering Magnetic Device to Treat Corneal Exposure

Condition: Paralytic Lagophthalmos · Corneal Exposure  ·  Sponsor: University of Illinois at Chicago

PhaseNA
Planned participants25
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Paralytic lagophthalmos can be difficult to treat and manage. It has a host of causes and effects, one of which (for the latter) is exposure keratopathy. Untreated, this can lead to corneal ulceration, inflammation, and potentially blindness. Despite a variety of attempts at treating this complex condition, none have satisfactorily reduced complications ranging from ease of use to aesthetics. With improvement in magnetic technology, however, that may change. Barmettler et al (2014) have demonstrated preliminary success of externally affixed magnets in closing both model and patient eyelids. As such, we hypothesize that magnetic devices can be used to treat corneal exposure by controlling eyelid position.

This description comes directly from the study's public registry record.

Talk to the study team

Van Ann Tran, MD  ·  312-996-9120  ·  annqtran@uic.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Illinois - Specialty Care BuildingChicago, Illinois, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06291818